Drug General Information (ID: DDIKTNFP78)
Drug Name			Leuprolide		Drug Info		Atomoxetine		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antineoplastics				Cns Stimulants/Adrenergic Uptake Inhibitors
Structure

Mechanism of Leuprolide-Atomoxetine Interaction (Severity Level: Moderate)
Increased risk of prolong QT interval Click to Show/Hide Mechanism Graph
Drug Name		Leuprolide				Atomoxetine
Mechanism		Prolong QT interval				Prolong QT interval
Key Mechanism Factor 1
		Factor Name		QT interval
		Factor Description		Long QT syndrome is a heart signaling disorder that can cause a fast, chaotic heartbeat (arrhythmia). Many people may not exhibit symptoms, and usually the condition is detected during routine medical tests. In others, the most common symptoms include: sudden fainting, palpitations, dizziness, seizures, sudden death.
Mechanism Description		Increased risk of prolong QT interval by the combination of Leuprolide and Atomoxetine

Recommended Action
Management		The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.

References
1	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
2	Product Information. Eligard (leuprolide). Sanofi Winthrop Pharmaceuticals, New York, NY.
3	Product Information. Firmagon (degarelix). Ferring Pharmaceuticals Inc, Tarrytown, NY.
4	Product Information. Lupron (leuprolide). TAP Pharmaceuticals Inc, Deerfield, IL.
5	Product Information. Plenaxis (abarelix). Praecis Pharmaceuticals Inc, Waltham, MA.
6	Product Information. Trelstar (triptorelin) Pharmacia and Upjohn, Kalamazoo, MI.
7	Product Information. Vantas (histrelin). Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc), Lexington, MA.
8	Product Information. Zoladex (goserelin). Zeneca Pharmaceuticals, Wilmington, DE.